PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

MLA

Ason, Brandon, et al. “PCSK9 Inhibition Fails to Alter Hepatic LDLR, Circulating Cholesterol, and Atherosclerosis in the Absence of ApoE.” Journal of Lipid Research, vol. 55, no. 11, Nov. 2014, pp. 2370–79. EBSCOhost, https://doi.org/10.1194/jlr.M053207.

APA

Ason, B., van der Hoorn, J. W. A., Chan, J., Lee, E., Pieterman, E. J., Nguyen, K. K., Di, M., Shetterly, S., Tang, J., Yeh, W.-C., Schwarz, M., Jukema, J. W., Scott, R., Wasserman, S. M., Princen, H. M. G., & Jackson, S. (2014). PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research, 55(11), 2370–2379. https://doi.org/10.1194/jlr.M053207

Chicago

Ason, Brandon, José W A van der Hoorn, Joyce Chan, Edward Lee, Elsbet J Pieterman, Kathy Khanh Nguyen, Mei Di, et al. 2014. “PCSK9 Inhibition Fails to Alter Hepatic LDLR, Circulating Cholesterol, and Atherosclerosis in the Absence of ApoE.” Journal of Lipid Research 55 (11): 2370–79. doi:10.1194/jlr.M053207.